tbuckley/cabot-search huggingface dataset:
Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer.
Authors: Janie Yue Zhang, Michael Cecchini, Shruti S. Desai, Kurt A. Schalper
Journal: Journal of Clinical Oncology (2022)

136 Background: O 6 -methylguanine DNA methyltransferase (MGMT) is the principal repair mechanism of DNA damage created by alkylating agents. Approximately 40% of colorectal cancers (CRC) exhibit MGMT promoter hypermethylation, expected to result in gene silencing. The role of MGMT as a biomarker is poorly understood, and quantitative measurement of MGMT protein has not been performed in CRC. We hypothesized that altered tumor MGMT would affect DNA damage response, modulate adaptive anti-tumor immune responses, and influence survival in CRC. Methods: We used multiplexed quantitative immunofluorescence (QIF) to study 4 clinically annotated retrospective patient cohorts treated from 2000 to 2017 at Yale, consisting of 400 formalin-fixed paraffin-embedded CRC cases represented in tissue microarray format. These included paired tumors and adjacent non-tumor colonic mucosa (n = 112 pairs in Cohort 1), paired primary CRC and lymph node metastases (n = 31 pairs in Cohort 2), and 2 cohorts with primary stage I-IV tumors (n = 250 in Cohort 3; n = 150 in Cohort 4). We established a QIF panel for simultaneous, localized measurement of DAPI (all cells), cytokeratin (CK; tumor epithelial cells), MGMT, γH2AX (DNA damage response), and CD8. The measurement of fluorescent signals in CK-positive tumor cells or CK-negative stromal cells was achieved using co-localization strategies and the AQUA QIF platform. Results: We identified lower MGMT protein levels in CRC cells than in non-tumor colonic epithelium (p &lt; 0.0001), and in lymph node metastases compared to paired primary CRC tumors (p = 0.0411). Using the visual detection threshold, tumor selective MGMT protein downregulation was identified in 20% of cases in Cohorts 3 and 4. Microsatellite instability-high (MSI-H) cases showed decreased tumoral MGMT protein compared to microsatellite stable (MSS) cases (p = 0.002). In Cohorts 3 and 4, low tumoral MGMT was consistently associated with increased CD8+ tumor infiltrating lymphocytes (p = 0.0472; p = 0.0002). The association between MGMT and γH2AX was inconsistent. The association between MGMT and CD8 was significant only in MSS cases (p = 0.0001) but not in MSI-H cases (p = 0.0979), supporting that the effect is not driven by MSI-H status. Tumor-selective MGMT downregulation evidenced by a low tumor-to-stroma ratio was associated with improved progression-free survival and overall survival in both Cohorts 3 and 4, but statistical significance was only seen in Cohort 3. Conclusions: MGMT protein downregulation occurs in 20% of CRCs and is associated with increased adaptive anti-tumor immune responses, mismatch repair (MMR) deficiency and better prognosis. MGMT deficiency may alter DNA repair in tumor cells and mediate the accumulation of antigenic mutations or neopeptides, independent from MMR status. Our results support a biomarker role of MGMT protein and suggest a role for immunotherapy combinations in MGMT deficient tumors.
Medical-Social Aspects in the Rehabilitation of Congenital Malformations Associated with Thalidomide
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tobacco and the Cardiovascular System: The Effects of Smoking and of Nicotine on Normal Persons
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intermittent compressive force induces cell cycling and reduces apoptosis in embryoid bodies of mouse induced pluripotent stem cells
Authors: Jeeranan Manokawinchoke, Phoonsuk Limraksasin, Hiroko Okawa, Prasit Pavasant, Hiroshi Egusa, Thanaphum Osathanon
Journal: International Journal of Oral Science (2022)

In vitro manipulation of induced pluripotent stem cells (iPSCs) by environmental factors is of great interest for three-dimensional (3D) tissue/organ induction. The effects of mechanical force depend on many factors, including force and cell type. However, information on such effects in iPSCs is lacking. The aim of this study was to identify a molecular mechanism in iPSCs responding to intermittent compressive force (ICF) by analyzing the global gene expression profile. Embryoid bodies of mouse iPSCs, attached on a tissue culture plate in 3D form, were subjected to ICF in serum-free culture medium for 24 h. Gene ontology analyses for RNA sequencing data demonstrated that genes differentially regulated by ICF were mainly associated with metabolic processes, membrane and protein binding. Topology-based analysis demonstrated that ICF induced genes in cell cycle categories and downregulated genes associated with metabolic processes. The Kyoto Encyclopedia of Genes and Genomes database revealed differentially regulated genes related to the p53 signaling pathway and cell cycle. qPCR analysis demonstrated significant upregulation of Ccnd1, Cdk6 and Ccng1. Flow cytometry showed that ICF induced cell cycle and proliferation, while reducing the number of apoptotic cells. ICF also upregulated transforming growth factor β1 (Tgfb1) at both mRNA and protein levels, and pretreatment with a TGF-β inhibitor (SB431542) prior to ICF abolished ICF-induced Ccnd1 and Cdk6 expression. Taken together, these findings show that TGF-β signaling in iPSCs enhances proliferation and decreases apoptosis in response to ICF, that could give rise to an efficient protocol to manipulate iPSCs for organoid fabrication.
Reply
Authors: W. Bob Meijboom, Matthijs F.L. Meijs, Joanne D. Schuijf, Maarten J. Cramer, Nico R. Mollet, Carlos A.G. van Mieghem, Koen Nieman, Jacob M. van Werkhoven, Gabija Pundziute, Annick C. Weustink, Alexander M. de Vos, Francesca Pugliese, Benno Rensing, J. Wouter Jukema, Jeroen J. Bax, Mathias Prokop, Pieter A. Doevendans, Myriam G. Hunink, Gabriel P. Krestin, Pim J. de Feyter
Journal: Journal of the American College of Cardiology (2009)
Educational Number: Corrections
Authors: Mr Watts, A Maca, P Allan, Bournemouth Alderson, P Aber Romb E, F Atkinson, Antitoxin Brevet, ; Mr, Chesterton Byrne, Mr Bidwell, R Batten, London Bown, C Campbell, Dublin Cameron, A Corthorn, J Craig, J Cuppaidge, Totnes Cotswold, J Coumbe, Huddersfield Chevers, E Diver, Shotley Bridge, ; Douglas-Crawford, ; Drake, L Drage, Hattleld Deltoid, Mr De La Court, E Deanesly, Wolverhampton Delta, A Tdutt, Oheltenham Duke, Eucaine Eyemes, ; Enquirer, W Freeman, H Ferguson, A Friel, P Freyer, W Ifarquharson, W Fenwict, W Reading, Mr Freyer, Mr Gooch, W Gilbert, Baden Baden, Stoke-On-Trent Gilbert, L Gamble, H Igladstone, P Gardiner, Calcutta Ghosh, J Gooding, Cheltenham Glasg, ; Gono-Coquette;, A Green, R Gibson, Hong Kong, Grange-Over-Sands Gwatkin, G Herman, G Hatton, F Hutchison, S Harris, C Hoar, J Hall, Mr Hosegood, Walsbam North, W Hedley, A Heys
Journal: BMJ (1901)

J. T. W. (Barrow-in-Furness).-The custoIml in rega.rd to permitting smok- ing among patients in the wards varies in different hospitals.In some it is permitted every evening for a limited time even by those confinedto bed, in others, probably in the majority, it is only permitted on special occasions, such as during Christmas festivities.Any objection that could be raised wolld probably have less force in respect of surgical than medical wards.The chief objection under the circumstances mentioned would prnbahly arise from the individual discomfort of any particular patient who disliked smoke or smoking.
TCT-503 Cut-off value of strut vessel distance on resolution of acute incomplete stent apposition at one month using serial optical coherence tomography after cobalt- chromium everolimus-eluting stent implantation in patients with stable coronary artery disease
Authors: Hideto Oda, Tomonori Itoh, Yohei Uchimura, Yuya Taguchi, Kyosuke Kaneko, Tsubasa Sakamoto, Iwao Goto, Masafumi Sakuma, Masaru Ishida, Yoshihiro Morino, Yoshiro Tsukiyama, Daisuke Terashita, Hiromasa Otake, Toshiro Shinke
Journal: Journal of the American College of Cardiology (2018)
Characteristics and trends in treatment utilization in young-onset cholangiocarcinoma.
Authors: Sarah Reddy, Suleyman Yasin Goksu, Nivan Chowattukunnel, David Hsieh, Salwan Al Matar, Nina Niu Sanford, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi
Journal: Journal of Clinical Oncology (2022)

386 Background: Although the incidence of cholangiocarcinoma is rising, little is known about the demographic and clinical characteristics of patients with young-onset cholangiocarcinoma (YOCC), diagnosed at age &lt; 50 years. The objective of this study was to compare patients with YOCC, and patients with typical-onset cholangiocarcinoma (TOCC; diagnosed age &gt;50 years), and to describe trends in treatment utilization and factors associated with survival in YOCC. Methods: We identified patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma from the National Cancer Database (NCDB) between 2004 and 2016. Patients were classified as either having YOCC or TOCC. Categorical variables were compared using the chi-square test with Bonferroni correction. Multivariate survival analyses were performed using the Cox-regression model after adjusting for age, gender, race/ethnicity, comorbidity index, insurance status, laterality, definitive surgery, radiotherapy, and chemotherapy. Results: We identified 26,346 patients, of which 2,520 had YOCC (9.6%, median age 44 years) and 23,826 had TOCC (90.4%, median age 68 years). Patients with YOCC were more likely to be non-White (YOCC 35.0% vs. TOCC 27.4%, p &lt;0.01) and had lower overall comorbidity burden. Patients with YOCC were more likely to present with stage IV disease (YOCC 50.5% vs. TOCC 43.5%, p &lt;0.001) and have intrahepatic cholangiocarcinoma (YOCC 56.0% vs. TOCC 45.5%, p&lt;0.001). Patients with YOCC were more likely to receive definitive surgery (YOCC 30.9% vs. TOCC 25.0%, p &lt;0.001) radiation (YOCC 27.7% vs. TOCC 19.0%, p&lt;0.001), and chemotherapy (YOCC 73.1% vs. TOCC 50.4%, p&lt;0.001). In adjusted analyses, patients with YOCC had a 21% decreased risk of death compared to patients with TOCC [HR 0.79 (95% CI 0.75-0.83), p&lt;0.001)]. This remained true for subgroups of patients with intrahepatic disease and those who underwent definitive surgery. Conclusions: YOCC constitutes a small but distinct subgroup of cholangiocarcinoma. Patients with YOCC were more likely to be non-White and present with intrahepatic cholangiocarcinoma disease. Despite being more likely to be diagnosed with advanced stage cholangiocarcinoma, patients with YOCC had better overall survival.
Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity
Authors: Işın Çakır, Colleen K. Hadley, Pauline Lining Pan, Rushita A. Bagchi, Masoud Ghamari-Langroudi, Danielle T. Porter, Qiuyu Wang, Michael J. Litt, Somnath Jana, Susan Hagen, Pil Lee, Andrew White, Jiandie D. Lin, Timothy A. McKinsey, Roger D. Cone
Journal: Nature Metabolism (2022)
1145-118 Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure
Authors: Takayoshi Tsutamoto, Chitose Ishikawa, Keijin Ohno, Hiroshi Sakai, Atsuyuki Wada, Masato Ohnishi, Minoru Horie
Journal: Journal of the American College of Cardiology (2004)
A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction
Journal: JAMA (1983)

The beta-Blocker Heart Attack Trial (BHAT) was a placebo-controlled, randomized, double-blind clinical trial of the long-term administration of propranolol hydrochloride to persons who had had at least one confirmed myocardial infarction. Among 3,837 patients followed up for an average of 25 months, coronary incidence, defined as recurrent nonfatal definite reinfarction plus fatal coronary heart disease, in the propranolol group was 10.0%, compared with 13.0% in the placebo group, a reduction of 23%. The incidence of definite nonfatal reinfarction was lower by 15.6%, and that of definite or probable nonfatal reinfarction by 14.7%. Among patients with a history of congestive heart failure (CHF), 14.8% of the propranolol-treated patients experienced definite CHF during the study, as did 12.6% of the placebo-treated patients. Among patients without history of CHF, the percentages experiencing CHF were 5.0% and 5.3%, respectively. In patients with no history of angina, the incidence of angina was 35.7% in the propranolol group and 34.4% in the placebo group. Among those who had a history of angina, the incidence was 66% in both groups. The BHAT analyses of nonfatal events reinforce the previous recommendation for the use of propranolol in the treatment of patients who have had a recent myocardial infarction and who have no contraindications to beta-blockers.
First Drug Available Under Parallel Track Policy
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1891)

(FROM OUR OWN CORRESPONDENT.) The impression has for some time been prevalent, that the various private hospitals in the city have been rather too much given to the practice of transferring dying patients to Bellevue Hospital, with a view to keeping down their own death-rate to as low a point as possible, without regard to the bad showing that the records of Bellevue would consequently make. A case in point was published in the newspapers last spring, where an old negro was found lying in the street in an unconscious condition on the lower part of University Place. An ambulance was summoned from St. Vincent's Hospital, which was quite near at hand; but the ambulance surgeon, after examining the man, and finding him to be in a dying condition, took him to Bellevue Hospital, more than a mile and a half distant, instead of to his own hospital. In commenting
Trans-radial coronary inetrvention for acute myocardial infarction Taiichiroh Meguro, Hidehiko Honda, Norio Endoh, Masayoshi terashima, Hisanao Takeda, Yuko Ito, Tatushi Otomo, Shinya Abe, kazunori, Ogat, Yasusuke miyazaki, Satomi Fujiwara, Osamu Kawashima, Ryuji Kuhara. Sendai Kohsei Hospital, sendai, Japan
Journal: Journal of the American College of Cardiology (2001)
Genetic factors influence ethanol-induced uroporphyria in Hfe (—/—) mice
Authors: Nadia Gorman, Heidi W. Trask, William J. Bement, Juliana G. Szakacs, George H. Elder, Dominic Balestra, Nicholas J. Jacobs, Judith M. Jacobs, Jacqueline F. Sinclair, Glenn S. Gerhard, Peter R. Sinclair
Journal: Hepatology (2004)

Two major risk factors for porphyria cutanea tarda (PCT) are alcohol consumption and homozygosity for the C282Y mutation in the hereditary hemochromatosis gene (HFE). We recently described an animal model for alcohol-induced uroporphyria, using Hfe(-/-) mice. In the present study we show that this effect is dependent on genetic background and ethanol dose. In the 129S6/SvEvTac (129) strain, treatment with 15% ethanol in the drinking water for 6.5 months produced an accumulation of hepatic uroporphyrin (URO) 4-fold higher than that observed with 10% ethanol, a 90% decrease in uroporphyrinogen decarboxylase activity (UROD), and further increased the activities of hepatic 5-aminolevulinate synthase (ALAS) and CYP1A2. Hepatic nonheme iron (NHFe) and hepatocyte iron staining were not further increased by 15% compared to 10% ethanol. Treatment of C57BL/6 Hfe(-/-) mice with 15% ethanol for 6.5 months did not increase hepatic URO. Although NHFe was increased by ethanol, the resulting level was only half that of ethanol-treated 129 Hfe(-/-) mice. ALAS induction was similar in both Hfe(-/-) strains. In wild-type 129 mice treated with ethanol for 6 to 7 months, administration of iron dextran increased hepatic URO accumulation and decreased UROD activity. In conclusion, this study demonstrates a strong effect of genetic background on ethanol-induced uroporphyria, which is probably due to a greater effect of ethanol on iron metabolism in the susceptible strain. (Hepatology 2004;40:942-950).
RE: Progression of Frailty in Survivors of Childhood Cancer: A St. Jude Lifetime Cohort Report
Authors: Junya Makiyama, Ryo Momosaki, Toshifumi Yodoshi, Takeshi Fujieda, Akihiro Ozaka, Atsushi Takayama, Takashi Yoshioka
Journal: JNCI Journal of the National Cancer Institute (2022)
Marfan syndrome: The diagnostic value of cardiac signs in a genotyped population Ioana Chiorescu, Catherine Boileau, Alain Beauchet, Gabriel Delorme, Catherine Guiti, Christine Muti, Olivier Dubourg, Guillaume Jondeau. H�pital Ambroise Par�, Cardiology, Boulogne, France
Journal: Journal of the American College of Cardiology (2001)
Book Notices
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutic regimens in advanced breast cancer
Authors: A. F. Hoge
Journal: JAMA (1975)

A retrospective study of the methods of treatment in 98 patients with advanced breast cancer over the past five years showed striking differences in remission rates, duration of remissions, and overall survival according to the method of treatment. Adrenalectomy and oophorectomy produced remissions in 58% of patients, with a median duration of 22 months. Survival curves were impressive and favored the surgically ablated group, who had a median survival of 32 months. Sixty-seven percent of responders continue to survive at four years. Chemotherapy with single agents produced remissions in 30% of patients, having a median duration of nine months. Additive endocrine therapy produced 33% to 36% remission rates, with median durations of 12 to 16 months. Responses were more frequent and longer lasting in older patients. Radiotherapy, when used without supplemental therapy, resulted in good local control, but a short median survival of 7.5 months. (<i>JAMA</i>231:1357-1360, 1974)
What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy?
Authors: Longbin Xiong, Jane K. Nguyen, Yulu Peng, Zhaohui Zhou, Kang Ning, Nan Jia, Jing Nie, Dongxiang Wen, Zeshen Wu, Gustavo Roversi, Diego Aguilar Palacios, Emily Abramczyk, Carlos Munoz-Lopez, Jack A. Campbell, Yun Cao, Wencai Li, Xuepei Zhang, Zhisong He, Xiang Li, Jiwei Huang, Jianzhong Shou, Jitao Wu, Minfeng Chen, Xiaofeng Chen, Jiaxuan Zheng, Congjie Xu, Wen Zhong, Zaishang Li, Wen Dong, Juping Zhao, Hailang Zhang, Junhang Luo, Jianye Liu, Fanghu Sun, Hui Han, Shengjie Guo, Pei Dong, Fangjian Zhou, Chunping Yu, Steven C. Campbell, Zhiling Zhang
Journal: European Urology (2022)
Epacadostat Shows Value in Two SCCHN Trials
Journal: Cancer Discovery (2017)

In the ECHO-202/KEYNOTE-037 and ECHO-204 trials reported at the 2017 Annual Meeting of the American Society of Clinical Oncology, patients with squamous cell carcinoma of the head and neck responded well to the combinations of epacadostat plus pembrolizumab and epacadostat plus nivolumab. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer.
Lack of adverse long-term prognostic effect of aspirin therapy in patients treated with angiotensin converting enzyme inhibitors after myocardial infarction. Results from a nationwide french registry of acute myocardial infarction Nicolas Danchin, Laurent Vaur, Sylvie Etienne, Jean Pierre Cambou, for the French USIK study Group. Hopital Europeen G. Pompidou, Paris, France, INSERM 518, Toulouse, France
Journal: Journal of the American College of Cardiology (2001)